High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals

Journal of Infection and Chemotherapy

Volumn 18, Issue 1, 2012, Pages 69-74

  Kubo, Shuku ^a   Tokumitsu, Akane ^a   Tomozawa, Takanori ^a   Kakuta, Masayo ^a   Yamashita, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

CS 8958; Influenza; Laninamivir; Long Acting neuraminidase inhibitor; Low susceptibility mutant in vivo

Indexed keywords

LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG EXPOSURE; DRUG LUNG LEVEL; DRUG TISSUE LEVEL; FEMALE; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; LUNG INFECTION; MOUSE; MOUSE MUTANT; NONHUMAN; REPEATED DRUG DOSE; VIRUS ISOLATION; VIRUS LOAD; VIRUS TITRATION;

EID: 84863434934     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0292-4     Document Type: Article

References (26)

1. Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1534-79.
2. Novel swine-origin influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-2615.
3. Gubareva L, Okomo-Adhiambo M, Deyde V, Fry AM, Sheu TG, Garten R, et al. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:433-5.
4. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (Lond). 2009;460:1021-5.
5. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother. 2010;54: 3671-7.
6. Lackenby A, Hungnes OS, Dudman G, Meijer A, Paget WJ, Hay AJ, et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eur Surveill. 2008;13:113-4.
7. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009; 325:197-201.
8. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-33. (Pubitemid 32151932)
9. Kiso M, Mitamura K, Sakai-Togawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364: 759-65. (Pubitemid 39165094)
10. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-42. (Pubitemid 46556469)
11. Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, Miura S, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009;53: 4845-51.
12. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-Acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol. 2010;50: 1319-29.
13. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-Acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53:186-92.
14. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M. Laninamivir prodrug CS-8958, a long-Acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010;54:1256-64.
15. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 2010;6:e1000786
16. Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 2010;6: e1001079
17. Kubo S, Kakuta M, Yamashita M. In vitro and in vivo effects of a long-Acting anti-influenza agent CS-8958 (laninamivir octanoate) against pandemic (H1N1) 2009 influenza viruses. Jpn J Antibiot. 2010;63:337-46.
18. Yamashita M. Laninamivir and its prodrug, CS-8958: long-Acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother. 2010;21:71-84.
19. Sugaya N, Ohashi Y. Long-Acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575-82.
20. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, MARVEL Study Group. Long-Acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a doubleblind, randomized, non-inferiority clinical trial. Clin Infect Dis. 2010;51:1167-75.
21. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM. Prevention and control of viral diseases. In: Principles of virology. Molecular biology, pathogenesis, and control. Washington, DC: American Society for Microbiology; 2000, p. 662-714.
22. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-5. (Pubitemid 23211439)
23. Yamashita M, Hirai T, Kubota K, Kubo S. Unique characteristics of long-Acting neuraminidase inhibitor laninamivir octanoate (CS-8958) that explains its long-lasting activity. Influenza Other Respir Viruses. 2011;5(suppl 1):93-5.
24. Saito T, Taylor G, Webster RG. Steps in maturation of influenza A virus neuraminidase. J Virol. 1995;69:5011-7.
25. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257-62.
26. Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011;52:432-7.